Itovebi (Inavolisib) Patent Expiration, LOE Window & CMS Spending

Itovebi (Inavolisib) by Roche / Genentech: FDA Orange Book core substance LOE 2038-04-26 (last listed 2038-06-14), 0 AB generics, $1.3M 2024 CMS Part D & Medicaid spend, and $22,867 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorRoche / Genentech
FDA Application & PathwayN219249 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2038-04-26
Last Listed Patent or Exclusivity Date2038-06-14
Orange Book Patents (*PED Extensions)7 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$1.3M
2024 Medicare Part D Spend$1.3M
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($22,867 intro WAC)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Roche / Genentech across sibling Meru public-data platforms.